Kiniksa Pharmaceuticals International Total Assets Growth & History (KNSA)
Kiniksa Pharmaceuticals International's total assets was $763.6M for fiscal 2025.
View full Kiniksa Pharmaceuticals International company overviewKiniksa Pharmaceuticals International annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $763.6M | $183.1M | +31.54% |
| 2024 | 2024-12-31 | $580.6M | $54.2M | +10.30% |
| 2023 | 2023-12-31 | $526.3M | $66.7M | +14.50% |
| 2022 | 2022-12-31 | $459.7M | $226.9M | +97.45% |
| 2021 | 2021-12-31 | $232.8M | −$116.7M | −33.38% |
| 2020 | 2020-12-31 | $349.5M | $94.9M | +37.30% |
| 2019 | 2019-12-31 | $254.5M | −$67.4M | −20.94% |
| 2018 | 2018-12-31 | $322.0M | $274.5M | +577.94% |
| 2017 | 2017-12-31 | $47.5M | — | — |
Kiniksa Pharmaceuticals International quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $896.1M | $235.0M | +35.54% |
| Q1 2026 | 2026-03-31 | $825.3M | $226.0M | +37.70% |
| Q4 2025 | 2025-12-31 | $763.6M | $183.1M | +31.54% |
| Q3 2025 | 2025-09-30 | $712.3M | $157.0M | +28.28% |
| Q2 2025 | 2025-06-30 | $661.1M | $118.7M | +21.89% |
| Q1 2025 | 2025-03-31 | $599.3M | $79.7M | +15.33% |
| Q4 2024 | 2024-12-31 | $580.6M | $54.2M | +10.30% |
| Q3 2024 | 2024-09-30 | $555.3M | $72.2M | +14.95% |
| Q2 2024 | 2024-06-30 | $542.4M | $58.1M | +12.00% |
| Q1 2024 | 2024-03-31 | $519.7M | $76.8M | +17.34% |
| Q4 2023 | 2023-12-31 | $526.3M | $66.7M | +14.50% |
| Q3 2023 | 2023-09-30 | $483.1M | $23.1M | +5.02% |
| Q2 2023 | 2023-06-30 | $484.3M | $273.8M | +130.00% |
| Q1 2023 | 2023-03-31 | $442.9M | $211.9M | +91.74% |
| Q4 2022 | 2022-12-31 | $459.7M | $226.9M | +97.45% |
| Q3 2022 | 2022-09-30 | $460.0M | $207.1M | +81.90% |
| Q2 2022 | 2022-06-30 | $210.6M | −$68.6M | −24.58% |
| Q1 2022 | 2022-03-31 | $231.0M | −$80.2M | −25.77% |
| Q4 2021 | 2021-12-31 | $232.8M | −$116.7M | −33.38% |
| Q3 2021 | 2021-09-30 | $252.9M | −$131.6M | −34.22% |
| Q2 2021 | 2021-06-30 | $279.2M | $7.8M | +2.86% |
| Q1 2021 | 2021-03-31 | $311.2M | $85.0M | +37.61% |
| Q4 2020 | 2020-12-31 | $349.5M | $94.9M | +37.30% |
| Q3 2020 | 2020-09-30 | $384.4M | $102.6M | +36.41% |
| Q2 2020 | 2020-06-30 | $271.4M | −$36.7M | −11.91% |
| Q1 2020 | 2020-03-31 | $226.1M | −$120.1M | −34.68% |
| Q4 2019 | 2019-12-31 | $254.5M | −$67.4M | −20.94% |
| Q3 2019 | 2019-09-30 | $281.8M | −$65.3M | −18.81% |
| Q2 2019 | 2019-06-30 | $308.1M | −$57.0M | −15.61% |
| Q1 2019 | 2019-03-31 | $346.2M | — | — |
| Q4 2018 | 2018-12-31 | $322.0M | $274.5M | +577.94% |
| Q3 2018 | 2018-09-30 | $347.1M | — | — |
| Q2 2018 | 2018-06-30 | $365.1M | — | — |
| Q4 2017 | 2017-12-31 | $47.5M | — | — |
Kiniksa Pharmaceuticals International total assets trends
Over the last five fiscal years, Kiniksa Pharmaceuticals International's total assets increased from $349.5M to $763.6M, a change of $414.2M. The latest reported quarter, Q2 2026, shows $896.1M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kiniksa Pharmaceuticals International source filings ↗